Myriad Genetics, Inc. (NASDAQ:MYGN)‘s stock had its “hold” rating reiterated by stock analysts at Cowen and Company in a research report issued on Friday. They currently have a $25.00 price objective on the stock. Cowen and Company’s price objective points to a potential upside of 1.21% from the company’s previous close.

Several other equities analysts have also recently weighed in on MYGN. Jefferies Group LLC reiterated a “hold” rating and set a $18.00 price objective on shares of Myriad Genetics in a research report on Friday, March 24th. Deutsche Bank AG lifted their price objective on shares of Myriad Genetics from $15.00 to $20.00 and gave the stock a “sell” rating in a research report on Monday, May 8th. BidaskClub upgraded shares of Myriad Genetics from a “sell” rating to a “hold” rating in a report on Friday, June 9th. Finally, J P Morgan Chase & Co restated an “underweight” rating and set a $16.00 price target on shares of Myriad Genetics in a report on Friday, June 30th. Five analysts have rated the stock with a sell rating, eight have given a hold rating and three have given a buy rating to the company. Myriad Genetics currently has an average rating of “Hold” and a consensus target price of $22.00.

Myriad Genetics (MYGN) opened at 24.70 on Friday. The company has a 50 day moving average price of $22.64 and a 200 day moving average price of $19.25. Myriad Genetics has a 12 month low of $15.15 and a 12 month high of $32.54. The stock has a market capitalization of $1.68 billion, a price-to-earnings ratio of 52.78 and a beta of 0.32.

Myriad Genetics (NASDAQ:MYGN) last posted its quarterly earnings data on Tuesday, May 2nd. The company reported $0.27 earnings per share for the quarter, topping the consensus estimate of $0.24 by $0.03. Myriad Genetics had a net margin of 4.26% and a return on equity of 10.53%. The firm had revenue of $196.90 million for the quarter, compared to analysts’ expectations of $188.89 million. Equities research analysts predict that Myriad Genetics will post $1.01 earnings per share for the current year.

TRADEMARK VIOLATION WARNING: This piece was posted by Daily Political and is the property of of Daily Political. If you are accessing this piece on another publication, it was illegally copied and republished in violation of United States & international copyright and trademark law. The legal version of this piece can be accessed at https://www.dailypolitical.com/2017/07/18/cowen-and-company-reiterates-hold-rating-for-myriad-genetics-inc-nasdaqmygn.html.

Several large investors have recently added to or reduced their stakes in MYGN. Ameritas Investment Partners Inc. purchased a new position in Myriad Genetics during the first quarter worth $112,000. Creative Planning raised its position in Myriad Genetics by 11.8% in the first quarter. Creative Planning now owns 6,371 shares of the company’s stock worth $122,000 after buying an additional 671 shares in the last quarter. State of Alaska Department of Revenue purchased a new position in Myriad Genetics during the first quarter worth $144,000. Karp Capital Management Corp purchased a new position in Myriad Genetics during the first quarter worth $223,000. Finally, Opus Point Partners Management LLC purchased a new position in Myriad Genetics during the fourth quarter worth $232,000.

About Myriad Genetics

Myriad Genetics, Inc is a molecular diagnostic company. The Company is engaged in the discovery, development and marketing of transformative molecular diagnostic tests. The Company operates through two segments: diagnostics and other. The diagnostics segment provides testing and collaborative development of testing that is designed to assess an individual’s risk for developing disease later in life, identify a patient’s likelihood of responding to drug therapy and guide a patient’s dosing to enable optimal treatment, or assess a patient’s risk of disease progression and disease recurrence.

Analyst Recommendations for Myriad Genetics (NASDAQ:MYGN)

Receive News & Ratings for Myriad Genetics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myriad Genetics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.